Societal CDMO, Inc. - Common Stock (NQ:SCTL)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 5, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Societal CDMO, Inc. - Common Stock

CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

April 08, 2024

From CoreRx, Inc.

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –

March 19, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

SOCIETAL CDMO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Societal CDMO, Inc. - SCTL

March 13, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB)

March 13, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

SOCIETAL CDMO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Societal CDMO, Inc. - SCTL

March 01, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)

February 29, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

SCTL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Societal CDMO, Inc. Is Fair to Shareholders

February 28, 2024

From Halper Sadeh LLC

Via Business Wire

Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO

May 03, 2023

Scalable Supply of CTx-1301 Ready to be Produced with Cingulate on Track to Meet Previously Announced Clinical Timelines for Phase 3 Trial Program

From Cingulate Inc.

Via GlobeNewswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.